June 1, 2023 (Charlottesville, VA) — ArcheMedX, a leading provider of behavioral science-based online learning and predictive analytics solutions, is proud to announce the success of its Risk Evaluation and Mitigation Strategy (REMS) Opioid Analgesic programs. These continuing medical education initiatives powered by the ArcheMedX platform are designed to improve the knowledge, competence, and confidence of healthcare providers in effectively diagnosing, treating, and managing patients with pain.

The ArcheMedX platform applies behavioral science to create and deliver more interactive online learning experiences that drive learners to absorb critical lessons and apply them to their practice. Leading medical education companies utilized the ArcheMedX platform to design highly engaging and effective REMS Opioid Analgesic programs that were made easily accessible to thousands of Healthcare Providers (HCPs) through the company’s seamlessly integrated audience distribution partners.

 The REMS Opioid Analgesic programs powered by the ArcheMedX platform demonstrated exceptional results and key data include:

• Over 54,000 unique learners, including physicians, nurse practitioners, physician associates, nurses, and other healthcare professionals engaged in 139,000 activity sessions
• Learners were highly engaged resulting in a 92% video completion rate
• Learners then demonstrated a 176% improvement in their knowledge, competence, and confidence in effectively diagnosing, treating, and managing patients with pain
• And 77% of learners strongly agreed or agreed that they planned to make a change in their practice based on what they learned in the educational program

These results highlight the effectiveness of the REMS Opioid Analgesic programs in addressing the critical need for healthcare providers to better understand and manage patients with pain while navigating the complexities of opioid prescribing.

The ArcheMedX platform delivers a more highly engaging and effective on-demand learning experience that ensures healthcare providers receive the highest-quality education. By offering the REMS Opioid Analgesic programs on this award-winning platform, ArcheMedX and its medical education partners demonstrate their commitment to combating the opioid crisis and supporting healthcare providers in their ongoing efforts to provide safe and effective pain management.

Dr. Brian McGowan, Chief Learning Officer at ArcheMedX, commented on the success of the REMS Opioid Analgesic programs, stating, “We are incredibly proud of the impact that these programs, powered by the ArcheMedX learning and analytics platform, have had on healthcare providers across the country. The continued growth in healthcare providers who have improved their ability to effectively manage patients with pain is a testament to the positive impact more effective continuing education can have in addressing the opioid crisis.”

ArcheMedX invites healthcare providers to join the growing community of learners who have benefitted from the REMS Opioid Analgesic programs and thanks the RPC and its member companies for supporting these educational programs.

 About ArcheMedX

ArcheMedX enables medical education companies, medical associations & societies, and health & life sciences companies to accelerate the development and adoption of new clinical treatments and evidence-based clinical practices. ArcheMedX is dedicated to advancing the quality of medical education and supporting healthcare providers in their ongoing efforts to stay current with the latest clinical guidelines and best practices. For more information, visit www.archemedx.com